Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: ABBV VRTX ALNY GILD INCY NBIX REGN BIIB BMY EXEL

| Held by: IWM VTI FNDA IWO VXF IBB XBI SCHA VTWO FESM

Index	RUT	P/E	29.53	EPS (ttm)	0.15	Insider Own	3.68%	Shs Outstand	162.68M	Perf Week	-6.75%
Market Cap	741.81M	Forward P/E	5.22	EPS next Y	0.87	Insider Trans	-0.90%	Shs Float	156.69M	Perf Month	11.76%
Enterprise Value	1.20B	PEG	-	EPS next Q	-0.07	Inst Own	91.89%	Short Float	5.75%	Perf Quarter	121.36%
Income	29.48M	P/S	2.19	EPS this Y	1066.67%	Inst Trans	1.33%	Short Ratio	2.02	Perf Half Y	418.18%
Sales	338.99M	P/B	-	EPS next Y	648.57%	ROA	7.51%	Short Interest	9.01M	Perf YTD	35.31%
Book/sh	-1.62	P/C	5.28	EPS next 5Y	-	ROE	-	52W High	5.78 -21.11%	Perf Year	116.11%
Cash/sh	0.86	P/FCF	10.97	EPS past 3/5Y	-88.04% -47.49%	ROIC	22.45%	52W Low	0.53 765.11%	Perf 3Y	-60.07%
Dividend Est.	-	EV/EBITDA	8.14	Sales past 3/5Y	-5.30% -3.89%	Gross Margin	99.44%	Volatility	7.30% 7.65%	Perf 5Y	-56.24%
Dividend TTM	-	EV/Sales	3.54	EPS Y/Y TTM	1236.48%	Oper. Margin	42.92%	ATR (14)	0.36	Perf 10Y	-40.98%
Dividend Ex-Date	-	Quick Ratio	1.13	Sales Y/Y TTM	-10.42%	Profit Margin	8.70%	RSI (14)	51.63	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.13	EPS Q/Q	906.14%	SMA20	-4.33%	Beta	0.22	Target Price	8.43
Payout	0.00%	Debt/Eq	-	Sales Q/Q	33.26%	SMA50	12.48%	Rel Volume	0.65	Prev Close	4.45
Employees	253	LT Debt/Eq	-	Earnings	Nov 10 BMO	SMA200	138.45%	Avg Volume	4.47M	Price	4.56
IPO	Feb 03, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	117.60% 63.38%	Trades		Volume	2,886,305	Change	2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$8
Apr-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-15-25	Downgrade	Jefferies	Buy → Hold
Apr-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Sep-09-24	Initiated	Leerink Partners	Market Perform	$5
Aug-08-24	Downgrade	CapitalOne	Overweight → Equal Weight	$12 → $4
Jan-17-24	Initiated	Craig Hallum	Buy	$21
Dec-14-23	Initiated	Wells Fargo	Overweight	$20
Nov-09-23	Initiated	Jefferies	Buy	$21
Sep-28-23	Initiated	JMP Securities	Mkt Outperform	$22
Sep-02-22	Initiated	CapitalOne	Overweight	$15
Apr-22-22	Initiated	Piper Sandler	Overweight	$16
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $9
Jun-17-20	Initiated	Northland Capital	Outperform	$14
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral	$14
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Feb-05-26 08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
Feb-04-26 09:06AM	Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating (Insider Monkey) -6.37%
Jan-26-26 02:11AM	Zacks.com featured highlights include IPG Photonics, Ironwood and Science Applications (Zacks)
Jan-23-26 10:33AM	4 Stocks Trading Near 52-Week High With More Upside Potential (Zacks)
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
03:25PM	Loading…
Jan-07-26 03:25PM	Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating (MarketBeat) -5.12%
08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks) +7.49%
Jan-03-26 07:20AM	Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M (TipRanks)
07:20AM	Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M (TipRanks)
Jan-02-26 12:21PM	Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 (Barrons.com) +26.71%
07:05AM	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance (Business Wire)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
Nov-28-25 10:11AM	Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations (Insider Monkey) -9.33%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
10:30AM	Loading…
Nov-21-25 10:30AM	Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? (Zacks)
Nov-13-25 10:36AM	IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +8.36%
Nov-11-25 09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks) +14.23%
Nov-10-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates (Zacks) +31.77%
07:21AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance (Business Wire)
Nov-06-25 07:35AM	Former blockbuster Linzess grows label with paediatric IBS-C approval (Pharmaceutical Technology)
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +10.16%
Oct-20-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks) +7.69%
Oct-16-25 07:56AM	BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-25 09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks) +8.78%
06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
09:50AM	Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-22-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:50AM	Loading…
Aug-21-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks) +7.27%
Aug-08-25 10:36AM	IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates (Zacks)
Aug-07-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:26AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance (Business Wire)
Jun-06-25 11:31AM	Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? (Zacks) +6.58%
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks) -11.63%
May-07-25 08:20AM	Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.55%
07:26AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports First Quarter 2025 Results (Business Wire)
May-06-25 10:00AM	Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 07:15AM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 04:25PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha) +9.23%
Apr-25-25 07:05AM	Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance (Business Wire)
Apr-22-25 04:05PM	Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support (Business Wire) +7.66%
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
Apr-15-25 09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks) +11.47%
07:12AM	Ironwoods shares sink as FDA demands new trial for lead drug (Pharmaceutical Technology)
Apr-14-25 07:00AM	Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide (Business Wire) -31.48%
Apr-13-25 10:44AM	The 1-Minute Market Report April 13, 2025 (Seeking Alpha)
Apr-10-25 10:49AM	Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth (Seeking Alpha)
09:25AM	Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? (Insider Monkey)
Apr-01-25 10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
Mar-31-25 08:05AM	The 1-Minute Market Report March 30, 2025 (Seeking Alpha)
Mar-27-25 04:05PM	Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing (Business Wire)
Mar-25-25 11:08AM	Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? (Zacks)
Mar-02-25 12:24PM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 02:14AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... (GuruFocus.com)
Feb-27-25 11:20PM	Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.26%
08:15AM	Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:20AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance (Business Wire)
Feb-26-25 08:13AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 04:00PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call (Business Wire)
Feb-05-25 06:28PM	Millrose Properties Set to Join S&P SmallCap 600 (PR Newswire) -8.06%
Jan-29-25 04:05PM	Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future (Business Wire) -38.17%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-20-24 09:15AM	Heres Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD) (Insider Monkey) +14.69%
Nov-26-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +5.07%
Nov-13-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 04:01AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.44%
Nov-07-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates (Zacks) -7.54%
07:20AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2024 Results (Business Wire)
Nov-06-24 07:29AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +12.25%
Oct-28-24 07:00AM	Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 (Business Wire)
Oct-24-24 04:00PM	Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call (Business Wire)
Oct-16-24 01:06PM	State Street Corp's Strategic Acquisition of Ironwood Pharmaceuticals Shares (GuruFocus.com)
08:58AM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
Oct-09-24 05:36PM	Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... (GuruFocus.com)
Sep-17-24 08:40AM	Implied Volatility Surging for Ironwood (IRWD) Stock Options (Zacks)
Sep-01-24 10:26PM	Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey) +7.58%
04:01PM	Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference (Business Wire)
Aug-09-24 10:56AM	Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates (Zacks)
Aug-08-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 (Zacks) -32.61%
07:16AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2024 Results (Business Wire)
Aug-01-24 10:01AM	Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline (Zacks)
Jul-25-24 04:00PM	Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call (Business Wire)
Jul-17-24 08:30AM	Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options (Zacks)
Jul-08-24 07:00AM	Memo Therapeutics AG appoints Paul Carter as Chairperson (GlobeNewswire)
Jun-12-24 07:00PM	Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD) (GuruFocus.com) -6.27%
Jun-10-24 07:00PM	Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ... (GuruFocus.com)
May-30-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 06:00AM	Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire) +5.61%
May-10-24 01:58PM	Ironwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical Advancements (GuruFocus.com)

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silver Ronald	Principal Accounting Officer	Jan 05 '26	Sale	4.60	35,416	162,914	276,809	Jan 07 04:05 PM
RONALD SILVER	Officer	Jan 05 '26	Proposed Sale	4.27	35,416	151,226		Jan 05 04:41 PM
Gaskins Tammi L	Chief Commercial Officer	Nov 17 '25	Sale	3.32	6,016	19,973	235,264	Nov 19 04:05 PM
Gaskins Tammi L	Officer	Nov 17 '25	Proposed Sale	3.37	6,324	21,312		Nov 14 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Aug 11 '25	Sale	0.84	1,316	1,105	241,280	Aug 13 04:05 PM
John Minardo	Chief Legal Officer	Aug 11 '25	Sale	0.84	7,754	6,513	400,378	Aug 13 04:05 PM
Martini Gregory S.	Chief Financial Officer	Aug 11 '25	Sale	0.84	1,265	1,063	182,545	Aug 13 04:05 PM
Silver Ronald	Principal Accounting Officer	Aug 11 '25	Sale	0.84	2,846	2,391	276,809	Aug 13 04:05 PM
John Minardo	Officer	Aug 11 '25	Proposed Sale	0.88	8,281	7,287		Aug 08 04:10 PM
Martini Gregory S.	Officer	Aug 11 '25	Proposed Sale	0.88	1,351	1,189		Aug 08 04:09 PM
Gaskins Tammi L	Officer	Aug 11 '25	Proposed Sale	0.88	1,406	1,237		Aug 08 04:08 PM
MCCOURT Thomas A	Chief Executive Officer	May 16 '25	Sale	0.58	13,353	7,745	1,147,281	May 20 04:14 PM
Gaskins Tammi L	Chief Commercial Officer	May 16 '25	Sale	0.58	2,563	1,487	242,596	May 20 04:10 PM
MCCOURT Thomas A	Officer	May 19 '25	Proposed Sale	0.59	14,661	8,650		May 16 04:07 PM
Gaskins Tammi L	Officer	May 19 '25	Proposed Sale	0.59	2,814	1,660		May 16 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 10 '25	Sale	1.76	139,064	244,753	1,160,634	Feb 12 09:00 PM
Silver Ronald	Principal Accounting Officer	Feb 10 '25	Sale	1.76	12,048	21,204	279,655	Feb 12 09:00 PM
Shetzline Michael	SVP, CMO, Head-Res&Drug	Feb 10 '25	Sale	1.76	41,269	72,633	554,007	Feb 12 09:00 PM
John Minardo	Chief Legal Officer	Feb 10 '25	Sale	1.76	38,938	68,531	408,132	Feb 12 09:00 PM
Martini Gregory S.	Chief Financial Officer	Feb 10 '25	Sale	1.76	12,052	21,212	183,810	Feb 12 09:00 PM
MCCOURT Thomas A	Officer	Feb 10 '25	Proposed Sale	1.94	142,454	276,361		Feb 07 04:21 PM
Shetzline Michael	Officer	Feb 10 '25	Proposed Sale	1.94	42,274	82,012		Feb 07 04:20 PM
John Minardo	Officer	Feb 10 '25	Proposed Sale	1.94	39,889	77,385		Feb 07 04:18 PM
Martini Gregory S.	Officer	Feb 10 '25	Proposed Sale	1.94	12,347	23,953		Feb 07 04:17 PM

Open in Screener

CYCN

Cyclerion Therapeutics Inc

Feb 06 • 04:00PM ET

1.10

+0.02 1.85 %

Healthcare • Biotechnology • USA • NASD

CYCN Cyclerion Therapeutics Inc daily Stock Chart

Peers: SRPT BMRN EXEL BLUE NBIX TBPH CRBP VKTX RDUS PRQR

| Held by: ONEQ VXF

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	30.85%	Shs Outstand	3.70M	Perf Week	-19.12%
Market Cap	4.32M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.31M	Perf Month	-38.89%
Enterprise Value	-0.25M	PEG	-	EPS next Q	-	Inst Own	4.78%	Short Float	6.68%	Perf Quarter	-37.14%
Income	-2.20M	P/S	1.52	EPS this Y	-	Inst Trans	3.19%	Short Ratio	0.09	Perf Half Y	-53.29%
Sales	2.85M	P/B	0.43	EPS next Y	-	ROA	-22.77%	Short Interest	0.15M	Perf YTD	-13.39%
Book/sh	2.58	P/C	0.95	EPS next 5Y	-	ROE	-24.80%	52W High	4.80 -77.08%	Perf Year	-75.45%
Cash/sh	1.16	P/FCF	-	EPS past 3/5Y	64.17% 57.72%	ROIC	-23.06%	52W Low	1.07 2.80%	Perf 3Y	-91.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-20.24% -15.00%	Gross Margin	-	Volatility	11.43% 10.01%	Perf 5Y	-98.23%
Dividend TTM	-	EV/Sales	-0.09	EPS Y/Y TTM	64.13%	Oper. Margin	-127.25%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.78	Sales Y/Y TTM	1371.65%	Profit Margin	-77.02%	RSI (14)	34.64	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.78	EPS Q/Q	-5.73%	SMA20	-21.29%	Beta	0.99	Target Price	4.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	351.03%	SMA50	-25.71%	Rel Volume	0.04	Prev Close	1.08
Employees	1	LT Debt/Eq	0.00	Earnings	-	SMA200	-53.19%	Avg Volume	1.82M	Price	1.10
IPO	Mar 18, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	76,311	Change	1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-21	Initiated	Truist	Buy	$14
Sep-24-21	Initiated	Cantor Fitzgerald	Overweight	$7
Jun-03-19	Initiated	Credit Suisse	Neutral

Jan-05-26 04:01PM	Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression (GlobeNewswire) +41.30%
Nov-10-25 09:16AM	EXCLUSIVE: Cycurion Wins $1 Million+ Contract To Modernize Federal Emergency Warning Network (Benzinga) +10.97%
Sep-23-25 04:01PM	Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company (GlobeNewswire) +7.62%
Dec-17-24 08:08AM	Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth (GlobeNewswire) -7.08%
Aug-07-24 07:00AM	Regina Graul, Ph.D., Promoted to Chief Executive Officer (GlobeNewswire)
07:52AM	Loading…
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +17.98%
May-08-24 08:52AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-05-24 06:53AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Dec-04-23 08:00AM	Cyclerion Appoints Regina Graul, Ph.D., as President (GlobeNewswire) -8.71%
Nov-30-23 06:16PM	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator (GlobeNewswire) +7.39% +14.06%
Aug-02-23 08:39PM	The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets (American City Business Journals)
Jul-31-23 07:00AM	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets (GlobeNewswire) +14.15%
Jun-01-23 04:00PM	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-15-23 01:00PM	Cyclerion Announces Reverse Stock Split (GlobeNewswire) -14.34%
02:59PM	Loading…
May-12-23 02:59PM	Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors (Benzinga) -25.10%
May-11-23 06:00PM	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 (GlobeNewswire)
06:00PM	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results (GlobeNewswire)
Apr-03-23 07:30AM	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement (GlobeNewswire) -17.98%
Mar-27-23 07:00AM	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases (GlobeNewswire) +23.71%
Mar-22-23 04:40PM	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results (GlobeNewswire) -11.54%
Nov-22-22 07:00AM	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company (GlobeNewswire) +34.31%
Nov-09-22 06:34AM	Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) (Simply Wall St.)
Oct-07-22 02:31PM	Cyclerion Therapeutics lays off nearly half of workforce (American City Business Journals) -9.66%
Oct-06-22 12:46PM	Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction (Benzinga) -37.57%
08:00AM	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy (GlobeNewswire)
Aug-09-22 05:35PM	Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -17.39%
04:00PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 09:22AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? (Simply Wall St.) +27.76%
Jul-28-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) (GlobeNewswire) +22.08%
07:00AM	Loading…
Jul-26-22 07:00AM	Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics Board of Directors (GlobeNewswire)
Jun-28-22 09:00AM	Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire) -5.55%
Jun-22-22 08:30AM	Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire)
Jun-17-22 11:20AM	Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies (Benzinga)
08:00AM	Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease (GlobeNewswire)
Jun-10-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) -20.18%
Jun-06-22 07:00AM	Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) +8.58%
May-11-22 09:30AM	As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year (Simply Wall St.) -8.17%
May-04-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results (GlobeNewswire) +8.62% -5.39%
Feb-27-22 06:39AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-24-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates (GlobeNewswire)
Feb-23-22 08:00AM	Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration (GlobeNewswire)
Feb-01-22 05:30AM	CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board (GlobeNewswire) +9.09%
Jan-26-22 08:00AM	Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimers Disease with Vascular Pathology (GlobeNewswire)
Dec-15-21 10:00AM	Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN) (Zacks) +9.38%
Nov-25-21 04:47AM	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year (Simply Wall St.)
Nov-11-21 05:32PM	Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Nov-09-21 04:01PM	Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -5.42%
Nov-08-21 12:00PM	Exclusive: Startup raises $27M to find brain-based biomarkers (American City Business Journals)
Oct-20-21 04:24PM	Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside (Benzinga) +10.90% -5.42%
Oct-11-21 03:34AM	David Greenspans Slate Path Capital is Buying Coinbase, Stitch Fix, and More (Insider Monkey)
Oct-10-21 09:37AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Sep-22-21 08:00AM	Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator (GlobeNewswire)
Sep-08-21 08:00AM	Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-21 07:19AM	Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-23-21 05:00PM	Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit (GlobeNewswire) +8.16%
Jul-29-21 05:00PM	Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -12.54%
Jul-22-21 04:30PM	Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimers Disease with Vascular Pathology at the Alzheimers Association International Conference 2021 (AAIC) (GlobeNewswire) +14.72%
Jul-12-21 02:24AM	Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares (Simply Wall St.)
Jul-09-21 06:14AM	Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers (Benzinga)
Jul-08-21 07:22PM	Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership (PR Newswire)
04:30PM	Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership (GlobeNewswire)
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise (Benzinga)
08:00AM	Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat (GlobeNewswire)
08:00AM	Cyclerion Therapeutics Announces $18 Million Private Placement (GlobeNewswire)
May-27-21 04:30PM	Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology (GlobeNewswire) +5.25%
May-25-21 07:00AM	Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:36AM	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares (Simply Wall St.)
Apr-27-21 09:00AM	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress (GlobeNewswire) -17.95%
Apr-26-21 07:00AM	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors (GlobeNewswire) +7.22%
Apr-21-21 07:30AM	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference (GlobeNewswire) +5.75%
Apr-20-21 07:00AM	Cyclerion Therapeutics to Host Pipeline Update Webinar (GlobeNewswire) +7.41%
Mar-24-21 04:05PM	TransMedics Appoints Stephanie Lovell to Board of Directors (PR Newswire) -6.80% +5.78%
Mar-22-21 02:23AM	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? (Simply Wall St.)
Mar-19-21 07:46AM	The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs (Benzinga)
Mar-18-21 05:00PM	Cyclerion Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Feb-25-21 07:00AM	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -9.48%
Jan-25-21 07:00AM	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards (GlobeNewswire)
Jan-21-21 12:52AM	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? (Simply Wall St.)
Jan-04-21 07:00AM	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-20 07:30AM	Cyclerion Announces Leadership Transitions (GlobeNewswire)
Dec-02-20 11:27PM	Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy? (Insider Monkey)
Nov-15-20 07:55AM	Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares (Simply Wall St.)
Nov-05-20 07:00AM	Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-20 01:09PM	Why Cyclerion Therapeutics Is Crashing Today (Motley Fool) -52.95%
10:07AM	Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study (Benzinga)
07:00AM	Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects (GlobeNewswire)
07:00AM	Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease (GlobeNewswire)
Oct-04-20 09:52AM	Health Check: How Prudently Does Cyclerion Therapeutics (NASDAQ:CYCN) Use Debt? (Simply Wall St.)
Sep-04-20 07:00AM	Cyclerion to Participate at Upcoming September 2020 Investor Conferences (GlobeNewswire)
Aug-25-20 07:00AM	Cyclerion Announces Translational Research Award from the Alzheimers Association Part the Cloud-Gates Partnership Grant Program (GlobeNewswire) +11.09%
Aug-20-20 11:01AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Aug-03-20 09:25AM	Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.81%
Jul-30-20 09:00AM	Cyclerion Therapeutics Completes $24 Million Private Placement (GlobeNewswire) +12.50%
Jul-17-20 07:00AM	Cyclerion Therapeutics Presentation at Biomarkers in Alzheimers Disease Summit (GlobeNewswire)
Jul-06-20 03:17PM	We're A Little Worried About Cyclerion Therapeutics's (NASDAQ:CYCN) Cash Burn Rate (Simply Wall St.)
Jul-05-20 02:45PM	Should You Buy Cyclerion Therapeutics, Inc. (CYCN)? (Insider Monkey)
Jun-18-20 04:01PM	Cyclerion to Host Webcast Investor Event on July 9, 2020 (GlobeNewswire) +18.04%
May-22-20 07:52AM	The Cyclerion Therapeutics (NASDAQ:CYCN) Share Price Is Down 72% So Some Shareholders Are Rather Upset (Simply Wall St.) +6.45%
Apr-10-20 07:00AM	Cyclerion Updates Corporate Progress (GlobeNewswire)

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

IRWD

Ironwood Pharmaceuticals Inc

CYCN

Cyclerion Therapeutics Inc

Upgrade your FINVIZ experience